rhenium has been researched along with 6-hydrazinopyridine-3-carboxylic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bryan, RA; Casadevall, A; Dadachova, E; Huang, X; Mints, L; Moadel, T; Nosanchuk, JD; Nosanchuk, JS; Ortiz, G; Revskaya, E; Schweitzer, AD; Zhang, T | 1 |
| Hnatowich, DJ; Liu, G | 1 |
| Cheng, PC; Chiang, PF; Chuang, TW; Lin, WJ; Luo, TY; Yeh, CH | 1 |
1 review(s) available for rhenium and 6-hydrazinopyridine-3-carboxylic acid
| Article | Year |
|---|---|
Labeling biomolecules with radiorhenium: a review of the bifunctional chelators.
Topics: Animals; Chelating Agents; Humans; Hydrazines; Hydroxamic Acids; Nicotinic Acids; Phosphines; Radioisotopes; Radiopharmaceuticals; Rhenium; Succinates | 2007 |
2 other study(ies) available for rhenium and 6-hydrazinopyridine-3-carboxylic acid
| Article | Year |
|---|---|
Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease.
Topics: Animals; Brain Diseases; Cell Line, Tumor; Chromatography, High Pressure Liquid; Female; Fluorescent Antibody Technique; Humans; Hydrazines; Immunotoxins; Kidney Diseases; Male; Melanins; Melanoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Nicotinic Acids; Peptides; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rhenium; Tissue Distribution; Xenograft Model Antitumor Assays | 2006 |
188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Radiation; Flow Cytometry; Humans; Hydrazines; Membrane Potential, Mitochondrial; Nicotinic Acids; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptor, ErbB-2; Rhenium; Trastuzumab | 2015 |